Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Title: QTX3544, a potent and selective G12V-preferring KRAS inhibitor, synergizes with EGFR inhibitors for enhanced anti-tumor activity Session Name: Late-Breaking Research: Experimental and Molecular ...
Their findings revealed that IFN-γ signaling activation and ERK/MAPK signaling inactivation contribute to age-related changes in the intestinal epithelium. Using mouse models, the researchers ...
In NF1, many of these medications work by blocking a specific cell signaling pathway called Ras/MAPK that is hyperactive in cells that have lost NF1 function due to gene mutation. When this signaling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback